We recently reported that Ceruvia Lifesciences, a private firm developing solutions for “debilitating headache disorders and difficult-to-treat psychiatric disorders, like OCD”, had submitted an Investigation New Drug (IND) application to the FDA to begin a Phase 2 clinical trial.
Well, it seems that the FDA was impressed with the potential as it has quickly approved the application and given the green light to start a Phase 2 clinical trial to determine the efficacy and safety of Ceruvia’s synthetic psilocybin (SYNP-101) in treating obsessive-compulsive disorder (OCD).
A little more about Ceruvia? Founder and CEO Carry Turnbull seems to be an experienced entrepreneur and psychedelic medicine advocate, working as a board member at both the Heffter Research Institute and the Usona Institute, two respected psychedelic research and advocacy groups. He also founded Freedom to Operate, the non-profit that challenged Compass Pathways’ controversial psilocybin patents.
A quick look at their developmental pipeline shows some decent advancements for a relatively new firm:
We’ll keep an eye out for more news on the trial and stay tuned to Microdose for more in-depth coverage and executive interviews. See the full press release below.
Ceruvia Lifesciences Receives FDA Investigational New Drug Approval for Psilocybin Obsessive-Compulsive Disorder Program Phase 2 Trial
Greenwich, Connecticut, June 27, 2022 – Ceruvia Lifesciences, a leading neurotransformational medicine biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug application for a Phase 2 clinical trial to determine the efficacy and safety of synthetic psilocybin (SYNP-101) in treating obsessive-compulsive disorder (OCD).
“With positive preliminary results from a Ceruvia funded pilot Phase 2 study taking place at Yale School of Medicine, we are excited to have received FDA approval to begin our Phase 2 clinical trial to examine the efficacy and safety of psilocybin in treating OCD”, said Carey Turnbull, Founder and CEO of Ceruvia Lifesciences. “With few effective treatment options available for the almost 4 million Americans who suffer from OCD, our Phase 2 clinical trial is an important step in helping these patients dramatically improve the quality of their lives.”
Ceruvia’s Phase 2, multicenter, randomized, double blind, active placebo controlled clinical trial will examine the safety and efficacy of synthetic psilocybin (SYNP-101) in treating OCD symptoms. The trial plans to enroll a total of 105 participants who will receive 25mg of SYNP-101 or the active placebo, niaicin. The primary endpoint of the trial is to determine the reduction in OCD symptoms for up to 12 weeks after a single administration of SYNP-101. Efficacy of treatment will be measured using the Yale-Brown Obsessive Compulsive Scale, the most used and validated tool for assessing the clinical severity of OCD symptoms. The trial will commence in the second half of 2022 and will be led by Principal Investigators Dr. Benjamin Kelmedi and Dr. Christopher Pittenger of Yale University School of Medicine.
About Ceruvia Lifesciences
Founded in 2017, Ceruvia Lifesciences is a clinical-stage biopharmaceutical company with a mission to improve the lives of underserved patients suffering from neurological and psychiatric disorders. Founded by Carey Turnbull, Ceruvia is relentlessly focused on the development and commercialization of neurotransformational medicines to deliver meaningful relief to patients suffering from hard-to-treat headache disorders, OCD and substance abuse disorder. For too long, these communities have been poorly understood and under-served. At Ceruvia, we believe they no longer have to live this way. Based on a long history of partnership with leading researchers at Yale University School of Medicine, NYU School of Medicine and Harvard Medical School, Ceruvia is undertaking clinical research in order to help them return to living their lives to the fullest. For more information, please visit www.ceruvialifesciences.com
Media inquiries:
Contact: Christopher Koddermann
Tel.: +41 (79) 434 25 78
E-Mail: chris@nyprg.org